JP2014148535A5 - - Google Patents

Download PDF

Info

Publication number
JP2014148535A5
JP2014148535A5 JP2014091125A JP2014091125A JP2014148535A5 JP 2014148535 A5 JP2014148535 A5 JP 2014148535A5 JP 2014091125 A JP2014091125 A JP 2014091125A JP 2014091125 A JP2014091125 A JP 2014091125A JP 2014148535 A5 JP2014148535 A5 JP 2014148535A5
Authority
JP
Japan
Prior art keywords
composition
dose
cytarabine
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014091125A
Other languages
English (en)
Japanese (ja)
Other versions
JP5856644B2 (ja
JP2014148535A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014148535A publication Critical patent/JP2014148535A/ja
Publication of JP2014148535A5 publication Critical patent/JP2014148535A5/ja
Application granted granted Critical
Publication of JP5856644B2 publication Critical patent/JP5856644B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2014091125A 2004-03-15 2014-04-25 Ｓｎｓ−５９５、及びその使用方法 Expired - Fee Related JP5856644B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55357804P 2004-03-15 2004-03-15
US60/553,578 2004-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012036919A Division JP2012140442A (ja) 2004-03-15 2012-02-23 Ｓｎｓ−５９５、及びその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015140309A Division JP6352863B2 (ja) 2004-03-15 2015-07-14 Ｓｎｓ−５９５、及びその使用方法

Publications (3)

Publication Number Publication Date
JP2014148535A JP2014148535A (ja) 2014-08-21
JP2014148535A5 true JP2014148535A5 (enExample) 2015-03-19
JP5856644B2 JP5856644B2 (ja) 2016-02-10

Family

ID=34993432

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2007503987A Expired - Fee Related JP5317472B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2007503972A Expired - Fee Related JP5096913B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2011135675A Pending JP2011225590A (ja) 2004-03-15 2011-06-17 Ｓｎｓ−５９５、及びその使用方法
JP2012036919A Pending JP2012140442A (ja) 2004-03-15 2012-02-23 Ｓｎｓ−５９５、及びその使用方法
JP2014091125A Expired - Fee Related JP5856644B2 (ja) 2004-03-15 2014-04-25 Ｓｎｓ−５９５、及びその使用方法
JP2014180862A Expired - Fee Related JP6261477B2 (ja) 2004-03-15 2014-09-05 Ｓｎｓ−５９５、及びその使用方法
JP2015140309A Expired - Fee Related JP6352863B2 (ja) 2004-03-15 2015-07-14 Ｓｎｓ−５９５、及びその使用方法
JP2016248041A Pending JP2017095471A (ja) 2004-03-15 2016-12-21 Ｓｎｓ−５９５、及びその使用方法
JP2018038834A Pending JP2018119977A (ja) 2004-03-15 2018-03-05 Ｓｎｓ−５９５、及びその使用方法

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2007503987A Expired - Fee Related JP5317472B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2007503972A Expired - Fee Related JP5096913B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2011135675A Pending JP2011225590A (ja) 2004-03-15 2011-06-17 Ｓｎｓ−５９５、及びその使用方法
JP2012036919A Pending JP2012140442A (ja) 2004-03-15 2012-02-23 Ｓｎｓ−５９５、及びその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014180862A Expired - Fee Related JP6261477B2 (ja) 2004-03-15 2014-09-05 Ｓｎｓ−５９５、及びその使用方法
JP2015140309A Expired - Fee Related JP6352863B2 (ja) 2004-03-15 2015-07-14 Ｓｎｓ−５９５、及びその使用方法
JP2016248041A Pending JP2017095471A (ja) 2004-03-15 2016-12-21 Ｓｎｓ−５９５、及びその使用方法
JP2018038834A Pending JP2018119977A (ja) 2004-03-15 2018-03-05 Ｓｎｓ−５９５、及びその使用方法

Country Status (23)

Country Link
US (12) US7968565B2 (enExample)
EP (4) EP1725233B1 (enExample)
JP (9) JP5317472B2 (enExample)
KR (1) KR101169825B1 (enExample)
CN (5) CN1997368B (enExample)
AT (2) ATE493982T1 (enExample)
AU (3) AU2005222622B2 (enExample)
BR (1) BRPI0508700A (enExample)
CA (3) CA2559652C (enExample)
CY (2) CY1109741T1 (enExample)
DE (2) DE602005025738D1 (enExample)
DK (3) DK1725233T3 (enExample)
ES (3) ES2566973T3 (enExample)
HU (1) HUE027266T2 (enExample)
IL (2) IL177946A (enExample)
MX (2) MX349188B (enExample)
NO (3) NO338058B1 (enExample)
NZ (2) NZ549557A (enExample)
PL (3) PL1725233T3 (enExample)
PT (2) PT1725233E (enExample)
SI (2) SI1725233T1 (enExample)
WO (2) WO2005089757A1 (enExample)
ZA (1) ZA200607248B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089757A1 (en) * 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
BRPI0515319A (pt) * 2004-09-17 2008-07-22 Cylene Pharmaceuticals Inc análogos de quinolona
US7652134B2 (en) * 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
JP2009504192A (ja) * 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
JP5374153B2 (ja) * 2005-09-02 2013-12-25 サネシス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸を使用する方法
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2007028171A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CA2654876A1 (en) * 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
PL2049109T3 (pl) * 2006-08-02 2016-05-31 Sunesis Pharmaceuticals Inc Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki
US20090093513A1 (en) * 2007-10-09 2009-04-09 Hamann Mark T Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
US8518872B2 (en) * 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
AU2014277779B2 (en) * 2007-10-22 2016-05-19 Sunesis Pharmaceuticals, Inc. METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
JP5936862B2 (ja) * 2009-02-27 2016-06-22 サネシス ファーマシューティカルズ， インコーポレイテッド Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
PE20150100A1 (es) 2012-02-27 2015-01-24 Agq Technological Corporate S A Monitoreo y control de las condiciones del suelo
IN2014KN02601A (enExample) 2012-04-24 2015-05-08 Vertex Pharma
ES2900061T3 (es) 2013-03-12 2022-03-15 Vertex Pharma Inhibidores de DNA-PK
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
WO2015000034A1 (en) * 2013-07-02 2015-01-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iii
SG11201602962PA (en) 2013-10-17 2016-05-30 Vertex Pharma Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
WO2025033367A1 (ja) * 2023-08-04 2025-02-13 湧永製薬株式会社 抗腫瘍剤併用療法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3021A (en) * 1843-03-30 Stove with elevated ovejst
US216316A (en) * 1879-06-10 Improvement in latches
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
CN1053668C (zh) * 1994-06-14 2000-06-21 大日本制药株式会社 新型化合物及其制法和抗肿瘤剂
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
DK0966683T3 (da) * 1997-01-13 2003-08-04 Kudos Pharm Ltd Assays, midler, terapi og diagnose vedrørende moduleirng af cellulær DNA-reparationsaktivitet
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
US6291643B1 (en) * 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
US6171857B1 (en) * 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
CA2332179C (en) * 1998-06-30 2011-06-28 Sloan-Kettering Institute For Cancer Research Uses of dna-pk
CA2363621A1 (en) * 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
US6670144B1 (en) 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) * 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
CA2408749A1 (en) * 2000-05-20 2001-11-29 Cancer Research Technology Limited Drug screening systems and assays
EP1351946A2 (en) * 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2877202A (en) * 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
EP1497470A2 (en) * 2002-04-05 2005-01-19 FISHEL, Richard, A. Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
EP1660473A2 (en) 2003-03-24 2006-05-31 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
WO2005089757A1 (en) 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2007028171A1 (en) 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CA2654876A1 (en) * 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
PL2049109T3 (pl) 2006-08-02 2016-05-31 Sunesis Pharmaceuticals Inc Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki
US8518872B2 (en) 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
JP5936862B2 (ja) 2009-02-27 2016-06-22 サネシス ファーマシューティカルズ， インコーポレイテッド Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法
CN101631081B (zh) 2009-08-12 2011-06-08 华为技术有限公司 一种多级交换网
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2014148535A5 (enExample)
JP2015227351A5 (enExample)
JP2014040437A5 (enExample)
EP3251674A3 (en) Antiviral azasugar-containing nucleosides
JP2016508134A5 (enExample)
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
WO2005105213A3 (en) Indole and azaindole derivatives with antitumor action
JP2017504611A5 (enExample)
EP4356912A3 (en) High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
JP2013526525A5 (enExample)
JP2011079858A5 (enExample)
WO2008016702A3 (en) Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
JP2016539157A5 (enExample)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
HK1198869A1 (en) Combination treatments for hepatitis c
JP2016510326A5 (enExample)
MY166288A (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
JP2015502926A5 (enExample)
JP2014533277A5 (enExample)
WO2011085643A8 (zh) 吡啶并环衍生物
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
RU2019142111A (ru) Усилитель противоопухолевого эффекта с применением нового соединения бифенила
JP2011500805A5 (enExample)
MX2010004350A (es) Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.